April 6, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, evaluate the clinical utility of circulating tumor DNA (ctDNA) in EGFR-mutant NSCLC. They discuss whether baseline ctDNA testing should be standard, and how ctDNA positivity and clearance may serve as prognostic and predictive biomarkers. The conversation highlights how ctDNA results can support, but not solely determine, decisions around treatment intensification.
Related Posts
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
The Emerging Role of ADCs in EGFR-Mutant NSCLC
Future Directions: Toward Personalized EGFR Therapy in NSCLC
The Evolution of Frontline Therapy in EGFR-Mutant NSCLC
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
